FDA Greenlights Immix Biopharma's IND for CAR-T Therapy NXC-201, Paving the Way for US Clinical Trials

Los Angeles, November 21, 2023 – Immix Biopharma, Inc. IMMX, a clinical-stage biopharmaceutical company, has made significant progress in advancing its lead therapeutic candidates in the fight against cancer and immunological diseases. The company proudly announced receiving approval from the U.S. Food and Drug Administration (FDA) for their Investigational New Drug (IND) application for NXC-201, a novel chimeric antigen receptor T-cell (CAR-T) therapy. This regulatory milestone authorizes IMMX to commence dosing patients within the United States, marking a pivotal step in bringing their innovative treatment closer to clinical application.

About NXC-201's IND Approval

The FDA's nod for NXC-201's IND application is a testimony to Immix Biopharma's robust research and development capabilities, promising to broaden treatment options for patients battling serious oncological illnesses. NXC-201 is engineered to harness the body's immune system, specifically T-cells, to identify and eliminate cancer cells more effectively.

Immix Biopharma's Dedication to Personalized Therapies

Immix Biopharma, headquartered in Los Angeles, California, with international operations including Australia, is at the forefront of personalized medicine, striving to develop therapies that are fine-tuned to individual patients’ needs. Their mission is to create treatments that are not only potent but also exhibit lower levels of toxicity, potentially improving overall treatment outcomes and quality of life for patients.

IMMX's Position in the Biopharmaceutical Industry

Stockholders of Immix Biopharma IMMX have been closely monitoring the company's progress. With the recent IND approval, investors are watching for potential impacts on IMMX's stock performance, as clinical advances often signal promising growth for biotech companies. Immix Biopharma's dedication to pioneering specialized therapies in oncology and inflammation is a beacon of innovation in the biopharmaceutical industry.

ImmixBiopharma, FDA, CAR-T